Our New Investment in Peptone

Peptone, the molecular computational physics company focused on protein drug discovery, today announced the successful completion of a $40 million Series A financing round.

June 9, 2022

Peptone will develop the world’s most advanced facility dedicated to solving complex and problematic intrinsically disordered protein structures at scale, pioneering a new class of potential therapeutic targets and drugs.

Kamil Tamiola, CEO of Peptone:

“Disordered proteins operate right at the point where physics becomes biology,” said Kamil Tamiola, Ph.D., Co-Founder and CEO of Peptone. “By taking a rigorous and computer-driven experimental physics approach to analyzing proteins, we can go beyond classical drug discovery approaches and observe protein behavior that algorithms like AlphaFold cannot. This new funding will allow us to further advance our platform and support the investigation of the disordered protein universe towards developing drugs of the future.”

Francis Ho, Ph.D., Partner at Walden Catalyst Ventures:

“Computational drug discovery is resurgent, but the missing piece is how to understand disordered proteins. We believe Peptone could be the key to completing this puzzle,” said Francis Ho, Ph.D., Partner at Walden Catalyst Ventures “The Peptone team possesses the right combination of world-class scientific expertise, deep collaboration with top pharma and biotech partners, and incredible energy and passion to move mountains.”

The round was led by F-Prime Capital and Bessemer Venture Partners, with participation from Walden Catalyst Ventures and existing investors, including Hoxton Ventures and dRX Capital, the venture arm of Novartis.

Read the full press release here.